S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ACRS · Aclaris Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Aclaris Therapeutics Inc (ACRS)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$3.81
+0.05
(+1.20%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$3.81
$3.73
$3.96
52-WEEK RANGE
$3.81
$1.93
$6.60
What's happening
- ACRS is up 1.20% today, trading at $3.81. — Live quote
- Volume today (188,011) is well below its 3-month average of 2,560,880. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.15 actual vs. $-0.16 estimated (+8.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 9
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ACRS
+25.25%
vs S&P 500
+12.47%
1-YEAR RETURN
ACRS
+87.56%
vs S&P 500
+73.00%
6-MONTH RETURN
ACRS
-5.28%
3-MONTH RETURN
ACRS
-33.74%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.15
Est. $-0.16
BEAT +8.1%
2026-04-26 (Q1 2026)
$-0.15
Est. $-0.16
BEAT +6.8%
2026-01-26 (Q4 2025)
$-0.16
Est. $-0.15
MISS -4.6%
2025-10-26 (Q3 2025)
$-0.12
Est. $-0.14
BEAT +12.9%
Valuation Measures & Ratios
Enterprise Value4$554.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)69.76
Price / Book75.93
EV4 / Revenue67.43
EV4 / EBITDA—
Profit Margin-921.50%
Operating Margin-1050.16%
Return on Equity (ROE8)-61.65%
Return on Assets (ROA9)-42.41%
Avg Volume (3M)2,560,880
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $759.1M | $495.6M | $230.2M | $168.5M | $191.1M |
| P/E | -10.64 | -7.63 | -4.37 | -3.43 | -3.78 |
| Price/Sales | 87.25 | 58.12 | 21.16 | 16.29 | 17.43 |
| Price/Book | 6.09 | 3.45 | 1.92 | 1.28 | 1.33 |
| EV/Revenue | 85.04 | 54.76 | 18.84 | 13.84 | 14.66 |
| EV/EBITDA | -9.07 | -6.19 | -3.22 | — | — |
| ROE | -57.29% | -45.22% | -43.89% | -37.26% | -35.12% |
| ROA | -39.72% | -32.69% | -30.03% | -25.95% | -25.54% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short18,191,280
Change from Prior Settlement+13.16%
% of Float—
Days to Cover (Short Ratio)6.48
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +87.6%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-08-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -8.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -921.5%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ACRS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $2.0M | $3.3M | $1.8M | $1.5M | $4.3M | $2.8M | $2.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$24.2M | -$22.2M | -$17.1M | -$18.4M | -$18.1M | -$10.5M | -$12.9M | -$18.9M |
| Net income | -$21.5M | -$19.8M | -$14.6M | -$15.4M | -$15.1M | -$7.6M | -$11.0M | -$16.9M |
| EPS (diluted) | $-0.15 | $-0.15 | $-0.12 | $-0.13 | $-0.12 | $-0.11 | $-0.15 | $-0.24 |
| EPS (basic) | $-0.15 | $-0.15 | $-0.12 | $-0.13 | $-0.12 | $-0.11 | $-0.15 | $-0.24 |
| Operating margin | -$1.5K | -$1.1K | -$520 | -$1.0K | -$1.2K | -$241 | -$465 | -$789 |
| Net margin | -$1.3K | -$993 | -$443 | -$868 | -$1.0K | -$175 | -$397 | -$706 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $179.7M | $198.7M | $160.5M | $175.5M | $189.1M | $198.1M | $220.3M | $182.4M |
| Total liabilities | $55.1M | $55.1M | $57.4M | $55.4M | $57.4M | $54.0M | $64.8M | $52.2M |
| Stockholders' equity | $124.6M | $143.6M | $103.1M | $120.1M | $131.7M | $144.1M | $155.6M | $130.2M |
| Total current assets | $97.8M | $110.2M | $96.3M | $100.6M | $104.2M | $108.8M | $126.0M | $132.3M |
| Total current liabilities | $28.2M | $27.4M | $28.6M | $25.6M | $26.8M | $21.5M | $31.6M | $18.8M |
| Cash & equivalents | $19.2M | $28.7M | $20.0M | $25.3M | $25.4M | $30.4M | $24.6M | $47.7M |
| Accounts receivable | — | — | — | — | $194.0K | $250.0K | $318.0K | $343.0K |
| Inventory | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $664.0K | $750.0K | $761.0K | $811.0K | $868.0K | $942.0K | $1.0M | $1.1M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $2.2M | $2.4M | $2.8M | $2.8M | $3.0M | $3.2M | $3.1M | $3.2M |
| Accounts payable | $15.5M | $14.7M | $13.2M | $9.2M | $8.8M | $6.4M | $4.7M | $7.7M |
| Accrued liabilities | $6.0M | $5.9M | $8.8M | $9.8M | $11.4M | $8.6M | $20.3M | $4.7M |
| Deferred revenue (current) | $4.0M | $4.0M | $3.9M | $3.9M | $3.9M | $3.9M | $3.9M | $3.8M |
| Other current liabilities | $2.8M | $2.8M | $2.8M | $2.7M | $2.7M | $2.7M | $2.7M | $2.7M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $1.3M | $1.4M | $1.6M | $1.7M | $1.9M | $4.3M | $4.4M | $2.2M |
| Common stock & paid-in capital | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K |
| Retained earnings | -$1.01B | -$987.6M | -$967.8M | -$948.0M | -$933.4M | -$917.9M | -$902.9M | -$806.3M |
| Accumulated other comprehensive income (loss) | -$304.0K | $22.0K | $610.0K | $597.0K | $482.0K | $434.0K | $97.0K | $427.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.8M | -$18.1M | -$13.1M | -$10.9M | -$10.0M | -$13.1M | -$8.9M | $22.0M |
| Investing cash flow | $10.3M | -$30.9M | $10.4M | $13.8M | $5.0M | $19.1M | -$88.7M | $2.8M |
| Financing cash flow | $91.0K | $57.8M | -$2.5M | -$3.0M | -$9.0K | -$275.0K | $74.6M | $22.0K |
| Free cash flow | -$19.9M | -$18.2M | -$13.2M | -$11.0M | -$10.0M | -$13.1M | -$8.9M | $22.0M |
| Capital expenditures | $58.0K | $13.0K | $24.0K | $23.0K | $21.0K | $43.0K | $0 | $0 |
| Depreciation & amortization | $107.0K | $102.0K | $102.0K | $110.0K | $114.0K | $128.0K | $143.0K | $179.0K |
| Share-based compensation | $2.7M | $3.2M | $2.9M | $2.9M | $3.1M | $3.5M | $2.9M | $3.0M |
| Change in accounts receivable | — | — | — | — | -$56.0K | -$68.0K | -$25.0K | $18.0K |
| Change in inventory | — | — | — | — | — | — | — | — |
| Change in accounts payable | $842.0K | $1.5M | $4.0M | $377.0K | $2.4M | $1.7M | -$3.0M | $393.0K |
| Purchases of investments | $8.9M | $51.7M | $4.6M | $5.2M | $19.9M | $10.0M | $70.4M | $14.3M |
| Tax withholding on stock comp | $23.0K | $250.0K | $162.0K | $0 | $9.0K | $275.0K | $333.0K | $10.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M |
| Gross profit | — | — | — | — | — |
| Operating income | -$76.4M | -$141.9M | -$97.4M | -$89.9M | -$89.7M |
| Net income | -$64.9M | -$132.1M | -$88.5M | -$86.9M | -$90.9M |
| EPS (diluted) | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
| EPS (basic) | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
| Operating margin | -$976 | -$758 | -$312 | -$302 | -$1.3K |
| Net margin | -$830 | -$705 | -$283 | -$292 | -$1.3K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57.0M | $53.9M |
| Stockholders' equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M |
| Total current assets | $96.3M | $126.0M | $128.9M | $231.6M | $205.0M |
| Total current liabilities | $28.6M | $31.6M | $31.0M | $21.9M | $22.9M |
| Cash & equivalents | $20.0M | $24.6M | $39.9M | $45.3M | $27.3M |
| Accounts receivable | — | $318.0K | $298.0K | $484.0K | $623.0K |
| Inventory | — | — | — | — | — |
| Property, plant & equipment | $761.0K | $1.0M | $1.6M | $1.1M | $1.3M |
| Goodwill | — | — | — | — | — |
| Intangible assets | — | — | $269.0K | $7.0M | $7.0M |
| Other non-current assets | $2.8M | $3.1M | $4.2M | $2.7M | $3.6M |
| Accounts payable | $13.2M | $4.7M | $8.9M | $10.4M | $10.0M |
| Accrued liabilities | $8.8M | $20.3M | $19.4M | $8.7M | $10.1M |
| Deferred revenue (current) | $3.9M | $3.9M | — | — | — |
| Other current liabilities | $2.8M | $2.7M | $2.6M | — | $693.0K |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | $1.6M | $4.4M | $3.1M | $1.6M | $2.2M |
| Common stock & paid-in capital | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K |
| Retained earnings | -$967.8M | -$902.9M | -$770.8M | -$682.3M | -$595.4M |
| Accumulated other comprehensive income (loss) | $610.0K | $97.0K | -$106.0K | -$897.0K | -$224.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$47.1M | -$20.1M | -$78.3M | -$67.6M | -$52.1M |
| Investing cash flow | $48.4M | -$69.8M | $46.2M | $12.6M | -$167.6M |
| Financing cash flow | -$5.9M | $74.5M | $26.7M | $72.9M | $225.1M |
| Free cash flow | -$47.2M | -$20.2M | -$79.6M | -$68.2M | -$52.4M |
| Capital expenditures | $111.0K | $121.0K | $1.3M | $605.0K | $308.0K |
| Depreciation & amortization | $454.0K | $807.0K | $863.0K | $797.0K | $923.0K |
| Share-based compensation | $12.4M | $10.9M | $20.5M | $15.0M | $14.1M |
| Change in accounts receivable | — | $20.0K | -$186.0K | -$139.0K | -$149.0K |
| Change in inventory | — | — | — | — | — |
| Change in accounts payable | $8.4M | -$4.2M | -$1.5M | $368.0K | $3.7M |
| Purchases of investments | $39.7M | $120.0M | $135.7M | $164.8M | $235.2M |
| Tax withholding on stock comp | $446.0K | $409.0K | $102.0K | $34.0K | $3.1M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ACRS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers74.6%
Shares Outstanding142,736,848
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12,723,026 | $67.3M | 8.91% | +87.0% | 2026-08-14 |
| BML Capital Management, LLC | 11,975,000 | $63.3M | 8.39% | -16.0% | 2026-08-07 |
| BlackRock, Inc. | 10,037,008 | $53.1M | 7.03% | +35.5% | 2026-08-07 |
| Deep Track Capital, LP | 9,345,000 | $49.4M | 6.55% | +0.0% | 2026-08-14 |
| Vivo Capital, LLC | 6,694,637 | $35.4M | 4.69% | +0.4% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,817,866 | $30.8M | 4.08% | +12.6% | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | 4,925,374 | $26.1M | 3.45% | +0.0% | 2026-08-14 |
| Rock Springs Capital Management LP | 4,330,532 | $22.9M | 3.03% | -3.2% | 2026-08-14 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,071,000 | $21.5M | 2.85% | +5.2% | 2026-08-14 |
| Decheng Capital LLC | 4,041,736 | $21.4M | 2.83% | +0.0% | 2026-08-14 |
| State Street Corp | 3,255,340 | $17.2M | 2.28% | +62.1% | 2026-08-07 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,190,058 | $16.9M | 2.23% | +31.6% | 2026-08-12 |
| BRAIDWELL LP | 2,142,348 | $11.3M | 1.50% | +26.1% | 2026-08-14 |
| BALYASNY ASSET MANAGEMENT L.P. | 2,023,470 | $10.7M | 1.42% | -39.8% | 2026-08-13 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,946,482 | $10.3M | 1.36% | +0.0% | 2026-08-07 |
| Kalehua Capital Management LLC | 1,832,365 | $9.7M | 1.28% | +37.0% | 2026-08-14 |
| CITADEL ADVISORS LLC | 1,762,081 | $9.3M | 1.23% | -21.7% | 2026-08-14 |
| Jones Hill Capital LP | 1,759,492 | $9.3M | 1.23% | +0.0% | 2026-08-13 |
| ACADIAN ASSET MANAGEMENT LLC | 1,641,472 | $8.7K | 1.15% | +6.6% | 2026-08-12 |
| Palo Alto Investors LP | 1,613,430 | $8.5M | 1.13% | +0.0% | 2026-08-14 |
| Woodline Partners LP | 1,611,054 | $8.5M | 1.13% | +8.4% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,465,735 | $7.8M | 1.03% | -11.5% | 2026-06-30 |
| PANAGORA ASSET MANAGEMENT INC | 1,356,152 | $7.2M | 0.95% | +170.0% | 2026-08-06 |
| Connor, Clark & Lunn Investment Management Ltd. | 1,209,886 | $6.4M | 0.85% | -14.7% | 2026-08-12 |
| MPM BioImpact LLC | 1,042,467 | $5.5M | 0.73% | +166.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-02-01 to 2026-08-01
Recent transactions
- Insiders have net sold 300,000 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Kolbeck Roland Wilhelm (Chief Scientific Officer) — Option exercise of 36,375 shares on 2026-08-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)300,000 sh(1 txns)
Net Shares-300,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kolbeck Roland Wilhelm | Chief Scientific Officer | Option exercise | 2026-08-01 | 36,375 |
| Mehra Anand | Reporting person | Option exercise | 2026-06-05 | 11,580 |
| SCHIFF ANDREW N | Reporting person | Option exercise | 2026-06-05 | 11,580 |
| Humphries William D. | Reporting person | Option exercise | 2026-06-05 | 11,580 |
| Molineaux Christopher P. | Reporting person | Option exercise | 2026-06-05 | 11,580 |
| MILANO VINCENT | Reporting person | Option exercise | 2026-06-05 | 11,580 |
| GOWEN MAXINE | Reporting person | Option exercise | 2026-06-05 | 11,580 |
| Hall Jesse Wayne | Chief Medical Officer | Option exercise | 2026-05-01 | 36,375 |
| Leonard Braden Michael | Reporting person | Open market sale | 2026-04-23 | 300,000 |
| Balthaser Kevin | Chief Financial Officer | Option exercise | 2026-03-01 | 2,375 |
| Loerop James | Chief Business Officer | Option exercise | 2026-02-03 | 20,875 |
| Walker Neal | CEO | Option exercise | 2026-02-03 | 63,475 |
| Davis Hugh M. | President and COO | Option exercise | 2026-02-03 | 18,675 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-01 | Kolbeck Roland Wilhelm | Chief Scientific Officer | Option exercise | 36,375 | — |
| 2026-08-01 | Kolbeck Roland Wilhelm | Chief Scientific Officer | Tax withholding | 12,385 | $5.20 |
| 2026-06-05 | Mehra Anand | Reporting person | Option exercise | 11,580 | — |
| 2026-06-05 | SCHIFF ANDREW N | Reporting person | Option exercise | 11,580 | — |
| 2026-06-05 | Humphries William D. | Reporting person | Option exercise | 11,580 | — |
| 2026-06-05 | Molineaux Christopher P. | Reporting person | Option exercise | 11,580 | — |
| 2026-06-05 | MILANO VINCENT | Reporting person | Option exercise | 11,580 | — |
| 2026-06-05 | GOWEN MAXINE | Reporting person | Option exercise | 11,580 | — |
| 2026-05-01 | Hall Jesse Wayne | Chief Medical Officer | Option exercise | 36,375 | — |
| 2026-05-01 | Hall Jesse Wayne | Chief Medical Officer | Tax withholding | 9,330 | $4.41 |
| 2026-04-23 | Leonard Braden Michael | Reporting person | Open market sale | 300,000 | $4.53 |
| 2026-03-01 | Balthaser Kevin | Chief Financial Officer | Option exercise | 2,375 | — |
| 2026-03-01 | Balthaser Kevin | Chief Financial Officer | Tax withholding | 677 | $2.87 |
| 2026-02-03 | Loerop James | Chief Business Officer | Option exercise | 20,875 | — |
| 2026-02-03 | Loerop James | Chief Business Officer | Tax withholding | 5,937 | $3.47 |
| 2026-02-03 | Walker Neal | CEO | Option exercise | 63,475 | — |
| 2026-02-03 | Walker Neal | CEO | Tax withholding | 18,611 | $3.47 |
| 2026-02-03 | Davis Hugh M. | President and COO | Option exercise | 18,675 | — |
| 2026-02-03 | Balthaser Kevin | Chief Financial Officer | Option exercise | 22,025 | — |
| 2026-02-03 | Balthaser Kevin | Chief Financial Officer | Tax withholding | 6,449 | $3.47 |
| 2026-02-01 | Balthaser Kevin | Chief Financial Officer | Option exercise | 14,750 | — |
| 2026-02-01 | Balthaser Kevin | Chief Financial Officer | Tax withholding | 4,984 | $3.51 |
| 2026-01-02 | Walker Neal | CEO | Option exercise | 29,150 | — |
| 2026-01-02 | Walker Neal | CEO | Tax withholding | 9,952 | $2.88 |
| 2026-01-02 | Loerop James | Chief Business Officer | Option exercise | 18,150 | — |
| 2026-01-02 | Loerop James | Chief Business Officer | Tax withholding | 6,171 | $2.88 |
| 2026-01-02 | Balthaser Kevin | Chief Financial Officer | Option exercise | 13,200 | — |
| 2026-01-02 | Balthaser Kevin | Chief Financial Officer | Tax withholding | 4,461 | $2.88 |
| 2026-01-01 | Balthaser Kevin | Chief Financial Officer | Option exercise | 7,500 | — |
| 2026-01-01 | Balthaser Kevin | Chief Financial Officer | Tax withholding | 2,250 | $3.01 |
| 2025-12-31 | Loerop James | Chief Business Officer | Option exercise | 73,750 | — |
| 2025-12-31 | Loerop James | Chief Business Officer | Tax withholding | 33,994 | $3.01 |
| 2025-12-31 | Balthaser Kevin | Chief Financial Officer | Option exercise | 73,750 | — |
| 2025-12-31 | Balthaser Kevin | Chief Financial Officer | Tax withholding | 19,934 | $3.01 |
| 2025-02-01 | Loerop James | Chief Business Officer | Tax withholding | 15,980 | $2.48 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 00:02 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-01 | View on SEC.gov → |
| 2026-06-08 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-08 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-08 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-08 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-08 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-08 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-04 | 8-K | 2026-06-04 | View on SEC.gov → |
| 2026-05-07 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about ACRS (Aclaris Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Yahoo Finance · 2026-10-21 -
ACRS Nov 2026 1.000 call (ACRS261120C00001000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-18 -
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Yahoo Finance · 2026-09-15 -
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Yahoo Finance · 2026-09-03 -
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
Yahoo Finance · 2026-08-06 -
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Finance · 2026-08-06 -
Aclaris Therapeutics GAAP EPS of -$0.15 beats by $0.01, revenue of $1.6M beats by $0.22M
Seeking Alpha · 2026-08-06 -
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
Yahoo Finance · 2026-07-01
No headlines in this category right now — try “All”.